2,3,5,6-tetrafluoroisonicotinamide | 16297-10-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2,3,5,6-tetrafluoroisonicotinamide
• 英文别名: Tetrafluor-isonicotinsaeureamid；2,3,5,6-tetrafluoropyridine-4-carboxamide
• CAS: 16297-10-2
• 化学式: C₆H₂F₄N₂O
• 分子量: 194.088
• InChiKey: MMSZWKIXQDRXTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2,3,5,6-四氟吡啶 在 正丁基锂 、 氨 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 37.5h， 生成 2,3,5,6-tetrafluoroisonicotinamide
  参考文献：
  名称：

  2,3,4,6-四氟吡啶及其衍生物的制备及反应

  摘要：

  从容易获得的3,5-二氯三氟吡啶开始，通过在受控条件下进行卤素交换，制得3-氯四氟吡啶，随后使用钯/氧化铝在250-250℃的氢进行加氢脱氯，已建立了可靠的2,3,4,6-四氟吡啶路线。 270℃。为了获得3，4-二取代的三氟吡啶，已经研究了3-硫代衍生物的形成和反应。已经开发了这种材料的途径，并且报道了它们转化成脱氮嘌呤衍生物作为产生反义核苷的潜在底物的方法。

  DOI：

  10.1016/s0022-1139(99)00189-x

文献信息

• The reactivity of isocyanides with pentafluoropyridine
  作者：Motahereh Irani、Reza Ranjbar-Karimi、Alireza Poorfreidoni、Hossein Mehrabi

  DOI：10.1007/s00706-021-02856-x

  日期：2021.11

  conditions in dry dimethyl sulfoxide was investigated. The reaction of pentafluoropyridine with toluenesulfonylmethyl isocyanide (TosMIC) was less selective, but the reactions of other isocyanides with pentafluoropyridine gave the desired 2,3,5,6-tetrafluoro-N-substituted isonicotinamide. The structures of all the compounds were confirmed by IR, 1H NMR, 19F NMR, and 13C NMR spectroscopy, X-ray crystallography

  研究了一些异氰化物与五氟吡啶在碱性条件下在干燥二甲基亚砜中的反应性。五氟吡啶与甲苯磺酰基甲基异氰化物 (TosMIC) 的反应选择性较低，但其他异氰化物与五氟吡啶的反应得到所需的 2,3,5,6-四氟-N-取代的异烟酰胺。所有化合物的结构均通过IR、1 H NMR、19 F NMR、13 C NMR光谱、X射线晶体学以及元素分析确证。 图形摘要
• [EN] DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR<br/>[FR] AGENTS DE MODULATION DE LA DIFFERENCIATION ET UTILISATIONS ASSOCIEES
  申请人：UNIV QUEENSLAND

  公开号：WO2005065686A1

  公开（公告）日：2005-07-21

  This invention discloses methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signalling pathway, especially the FGF-1 or FGF-2 signalling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma and lipomatosis.

  该发明揭示了调节前脂肪细胞分化潜能和/或增殖的方法和药剂。更具体地，本发明揭示了调节成纤维细胞生长因子（FGF）信号通路的方法和药剂，特别是FGF-1或FGF-2信号通路，用于治疗或预防与脂肪相关的疾病，包括但不限于肥胖、脂肪瘤和脂肪增生。
• HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE
  申请人：Sugen, Inc.

  公开号：EP1066257A2

  公开（公告）日：2001-01-10
• Differentiation modulating agents and uses therefor
  申请人：Prins Bernhard Johannes

  公开号：US20050282733A1

  公开（公告）日：2005-12-22

  The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
• DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR
  申请人：Verva Pharmaceuticals, Inc.

  公开号：US20140221455A1

  公开（公告）日：2014-08-07

  The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.